Selpercatinib is the first drug from Loxo’s pipeline that Lilly has brought to market. Prior to the acquisition, Loxo won approval of Vitrakvi, which targets a different genetic mutation and is sold by Bayer AG. Although the company will continue to pursue «higher-risk, high reward» drug candidates such as pegilodecakin, these will be a smaller[…]